Manager	Title	Age	Since
Alexander Rabinovitch CEO	Chief Executive Officer	55	24/12/2019
Amos Cohen DFI	Director of Finance/CFO	47	01/03/2020
Itai Kabiljo LAW	General Counsel	-	01/04/2022

Director	Title	Age	Since
Lennie Michelson Grinbaum BRD	Director/Board Member	50	03/09/2015
David Salton BRD	Director/Board Member	66	14/12/2014
Alexander Rabinovitch CHM	Chairman	55	13/02/2025

More insiders

InterCure Ltd is an Israel-based company primarily enagged in cannabis industry. Thorugh its wholly owned subsidiary Canndoc the Company operates as licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products.

Employees

Sector

Healthcare Facilities & Services

More about the company

Market Cap	15Cr 43Cr 13Cr 12Cr 11Cr 21Cr 1.39TCr 21Cr 138.14Cr 54Cr 681.77Cr 55Cr 54Cr 2.36TCr	P/E Ratio 2024	-4.01x	P/E Ratio 2025	-4.87x
Enterprise Value	28Cr 82Cr 24Cr 23Cr 21Cr 40Cr 2.68TCr 40Cr 266Cr 103.9Cr 1.31TCr 106.45Cr 104.19Cr 4.54TCr	EV / Sales 2024	1.69x	EV / Sales 2025	1.16x
Free-Float	73.95%	Yield 2024 *	-	Yield 2025	-

15/06	InterCure Starts Review of US Medical Cannabis Opportunities; Completes Initial Closing of Botanico Acquisition	MT
01/05	InterCure Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04/03	InterCure Receives Noncompliance Notice From Nasdaq	MT
04/03	InterCure receives Nasdaq notification regarding minimum bid requirement	RE
19/02	InterCure announces preliminary estimated 2025 revenue of NIS 265 million, positive adjusted EBITDA and cash of NIS 43 million	RE
19/12	InterCure Ltd on Dec 15, became aware that Bazelet Group of Companies has initiated Restructuring proceedings before the Israeli district court	RE
03/11	Cannasoul Analytics Ltd. announced that it expects to receive funding from InterCure Ltd.	CI
03/11	InterCure Ltd. Enters into A Collaboration Agreement with Cannasoul R&D Ltd	CI
08/25/08	InterCure Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
08/25/08	Intercure reports first half 2025 results with NIS 130 million in revenue and positive operating cash flow	RE
08/25/08	InterCure Ltd H1 2025 revenue NIS 130 million	RE
20/25/20	Sector Update: Health Care Stocks Mixed Late Afternoon	MT
19/25/19	InterCure to Acquire Cannabis Brand Botanico in Two-Phase Deal	MT

15/06	InterCure Initiates Strategic Review of U.S. Medical Cannabis Opportunities Following Historic Federal Rescheduling and Completes the Initial closing of Botanico Acquisition	AQ
01/05	InterCure Announces 2025 Results with NIS 270 Million in Revenue and Positive Operating Cash Flow	AQ
04/03	InterCure Receives Nasdaq Notification Regarding Minimum Bid Requirement	AQ
19/02	InterCure Announces Preliminary Estimated 2025 Revenue of NIS 265 Million, Positive Adjusted EBITDA and Cash¹ of NIS 43 Million	AQ
03/11	InterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical Innovation	AQ

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
INTERCURE LTD.	+0.22%	-0.51%	-	-	4.92Cr
ORGANIGRAM GLOBAL INC.	-4.03%	-5.30%	-24.74%	-35.00%	15Cr
CANNARA BIOTECH INC.	-1.18%	+0.60%	+36.59%	+84.62%	12Cr
ASCEND WELLNESS HOLDINGS, INC.	0.00%	-8.62%	+82.76%	-20.90%	11Cr
JUSHI HOLDINGS INC.	+1.20%	-9.30%	+75.27%	+16.65%	9.51Cr
Average	-0.76%	-1.98%	+42.47%	+11.34%	11.83Cr
Weighted average by Cap.	-1.19%	-1.54%	+35.39%	+8.99%

	2024	2025
Net sales	24Cr 69Cr 21Cr 19Cr 18Cr 33Cr 2.26TCr 34Cr 223.98Cr 87Cr 1.11TCr 90Cr 88Cr 3.83TCr	27Cr 78Cr 23Cr 21Cr 20Cr 38Cr 2.55TCr 38Cr 253.38Cr 99Cr 1.25TCr 101.4Cr 99Cr 4.33TCr
Net income	-6.78Cr -20Cr -5.84Cr -5.38Cr -5.04Cr -9.48Cr -640.71Cr -9.57Cr -64Cr -25Cr -313.76Cr -25Cr -25Cr -1.09TCr	-3.57Cr -10Cr -3.08Cr -2.83Cr -2.66Cr -4.99Cr -337.49Cr -5.04Cr -33Cr -13Cr -165.27Cr -13Cr -13Cr -571.89Cr
Net Debt	13Cr 38Cr 11Cr 11Cr 9.88Cr 19Cr 1.25TCr 19Cr 124.49Cr 49Cr 614.39Cr 50Cr 49Cr 2.13TCr	14Cr 40Cr 12Cr 11Cr 10Cr 19Cr 1.29TCr 19Cr 127.85Cr 50Cr 630.99Cr 51Cr 50Cr 2.18TCr

InterCure Ltd. Share Price TEL AVIV STOCK EXCHANGE

Stocks

INCR

IL0011063760

Healthcare Facilities & Services

Valuation: InterCure Ltd.

Latest news : InterCure Ltd.

Press Releases: InterCure Ltd.

News in other languages: InterCure Ltd.

Quotes and Performance

Managers and Directors: InterCure Ltd.

Medical Farming

Financials

Company Profile